ArticleEuropean heart journal. Case reports2026
Immunoglobulin A lambda multiple myeloma- related light-chain cardiac amyloidosis presenting with progressive heart failure with preserved ejection fraction: a multimodality imaging case report.
Article in European heart journal. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cardiac involvement is the main determinant of prognosis in immunoglobulin light-chain (AL) amyloidosis, but may be under-recognized in patients with multiple myeloma (MM), particularly when classic electrocardiographic or cardiac magnetic resonance features are absent. Early recognition therefore relies on integration of cardiac biomarkers and multimodality imaging when tissue biopsy or scintigraphic subtyping is impractical. Case summary: A 74-year-old man with immunoglobulin A lambda MM and immune thrombocytopenic purpura developed progressive heart failure with preserved ejection fraction (HFpEF), increased left ventricular (LV) wall thickness, and markedly elevated N-terminal pro-B-type natriuretic peptide (NT-proBNP; 7164 pg/mL). Serial electrocardiograms did not demonstrate classic low voltage. Cardiac magnetic resonance revealed diffuse non-ischaemic late gadolinium enhancement consistent with an infiltrative cardiomyopathy. Bone-avid scintigraphy was non-contributory in the context of MM. A working diagnosis of Conclusion: This case highlights real-world diagnostic and management challenges of AL cardiac amyloidosis in MM, particularly when electrocardiography and scintigraphy are equivocal, underscoring the importance of early suspicion, multimodality imaging, and close cardio-haematologic collaboration. Discussion: This case illustrates real-world diagnostic challenges of AL cardiac amyloidosis (AL-CA) in MM when electrocardiography (ECG) and scintigraphy are equivocal. Clinicians should suspect AL-CA when HFpEF coexists with LV thickening and abnormal LA burden. Management emphasizes euvolaemia, cautious afterload reduction, and early haematology-cardiology co-management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.